Landiolol
Sponsors
Hirosaki university hospital, Hospices Civils de Lyon, University Hospital, Caen, CMC Ambroise Paré, Centre Hospitalier Universitaire, Amiens
Conditions
Atrial FibrillationAutonomic DysfunctionBeta BlockerBeta-blockerCardiac ArrestCardiac FailureCardiac SurgeryCardiovascular (CV) Risk
Phase 1
Phase 3
Landiolol in Postoperative Atrial Fibrillation
CompletedNCT03779178
Start: 2019-01-17End: 2019-12-04Updated: 2025-08-06
Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
CompletedNCT04607122
Start: 2021-01-27End: 2023-07-22Updated: 2023-08-25
Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility
RecruitingNCT04748796
Start: 2021-02-01End: 2027-09-30Target: 360Updated: 2025-08-24
LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS)
RecruitingNCT04931225
Start: 2022-07-18End: 2026-07-31Target: 44Updated: 2025-08-01
Phase 4
Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery
NCT04223739
Start: 2019-12-13End: 2022-06-01Target: 380Updated: 2020-01-10
Landiolol in Mitral Valve Surgery
RecruitingNCT06793670
Start: 2025-01-28End: 2027-12-31Target: 1500Updated: 2025-12-29
LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery
Not yet recruitingNCT07168421
Start: 2025-10-31End: 2028-03-01Target: 114Updated: 2025-09-11